About Us
Our Company
Our Team
Directors
Contact
Our Science
VAAST Platform
Mucosal Immunity
Platform Difference
Pipeline
COVID-19
Norovirus
Influenza
HPV
Publications
Investors
Careers
Vaxart Guiding Principles
Benefits
Open Positions
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
September 10, 2025
Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025
September 3, 2025
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors
September 2, 2025
Vaxart, Inc. Stockholder Fireside Chat
August 21, 2025
Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
August 13, 2025
Vaxart CEO Issues Letter to Stockholders
August 8, 2025
Vaxart to Host Second Quarter 2025 Business Update and Financial Results Conference Call on August 13
August 6, 2025
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
June 11, 2025
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
June 11, 2025
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
June 11, 2025
1
2
3
Next Page
→
